Clinical Trial Update: CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update assessing a dual CD19/BCMA-targeted CAR T-cell therapy for relapse/refractory autoimmune diseases, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anca-associated Vasculitis
• Connective Tissue Disease-associated Thrombocytopenia
• Inflammatory Myopathy
• Systemic Lupus Erythematosus
• Systemic Lupus Erythematosus with Immune Thrombocytopenia
• Systemic Sclerosis

Drugs mentioned

• CD19/BCMA dual-targeting CAR T-cell therapy

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Systemic Lupus Erythematosus, Systemic Sclerosis (SSc) | Phase 1 | Status: RECRUITING